Smith+Nephew Awarded Federal Contract for Negative Wound Pressure Therapy Systems

Smith+Nephew is providing its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems to the U.S. government under a 10-year* contract worth up to $75 million, courtesy of the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA). 

The RENASYS TOUCH NPWT System has demonstrated clinical efficacy^1,2,3,4 and operational fitness including portability,² an intuitive interface,^5,6,7 and the ability to provide a range of therapy modes, set points and cycle times that allow individualized patient care. The system will support military medical providers to administer therapy through prolonged casualty care, first surgical intervention, aeromedical transport, and definitive care in military treatment facilities. RENASYS TOUCH NPWT is manufactured in the United States.  

“Future conflicts will be more difficult and complex. This implies medical devices and treatments will need to be simplified and more intuitive to be used farther forward by a wide range of providers. RENASYS TOUCH NPWT will provide that simplified negative pressure wound therapy solution to the military care continuum for warfighters who need it most,” said Dennis Lyons, MSG (ret), SO-ATP and senior director, Military and Federal Health, at Smith+Nephew. 

Last year, the company reached a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to partner to transform wound and burn care in the armed forces.⁸  

Smith+Nephew has long supported military medical needs, beginning with the first field dressing dating back to World War I. Today, the firm’s commitment to innovation in wound care continues through an extensive Advanced Wound Management portfolio designed to meet complex clinical needs and help healthcare providers reduce human and economic consequences of wounds.²

Smith+Nephew is focused on the repair, regeneration, and replacement of soft and hard tissue. Its 17,000 employees help develop and apply new technologies across three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in Hull, United Kingdom, in 1856, the company now operates in around 100 countries and generated $5.8 billion in 2024 sales.

* Five years plus five one-year options

References
¹ Smith+Nephew 2018. Results Sheet for the RENASYS TOUCH PCS Outcomes in Flaps. Internal Report. ST924A.
² Forlee M, Zyl LV, Louw H, Nel J, Fourie N, Hartley R. A randomised controlled trial to compare the clinical efficacy and acceptability of adjustable intermittent and continuous Negative Pressure Wound Therapy (NPWT) in a new portable NPWT system. Poster presented at: European Wound Management Association (EWMA)2018; Krakow, Poland.
³ Wounds International 2020. Retrospective chronic and postsurgical wound case series: Understanding RENASYS TOUCH. London, UK.
⁴ Frear CC, Cuttle L, McPhail M, Chatfield MD, Kimble RM, Griffin BR. Randomized clinical trial of negative pressure wound therapy as an adjunctive treatment for small-area thermal burns in children. BJS. 2020;107(13):1741 – 1750.
⁵ Forlee M, Nel J, Richardson J, Rossington A, Cockwill J, Smith J. An interim analysis of device functionality and usability of RENASYS™ TOUCH – a new portable Negative Pressure Wound Therapy (NPWT) system. Poster presented at: Wounds UK2016; Harrogate, UK.
⁶ Smith+Nephew 2016. Smith and Nephew’s RENASYS Touch Device Features – Software features. Internal Report. DS/16/179/R. 
⁷ Smith+Nephew 2016. Smith and Nephew’s RENASYS Touch Device – User Validation. Internal Report. DS/16/174/R. 
⁸ https://www.smith-nephew.com/en/news/2024/02/28/20240228-smith-nephew-and-u-s-army-institute-of-surgical-research-to-engage